<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02253394</url>
  </required_header>
  <id_info>
    <org_study_id>CAPS_PAH</org_study_id>
    <nct_id>NCT02253394</nct_id>
  </id_info>
  <brief_title>The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study</brief_title>
  <official_title>The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (The CAPS-PAH Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary
      Arterial Hypertension (PAH) will increase exercise capacity. We also want to find out if
      spironolactone and ambrisentan effect the cardiac output (amount of blood the heart pumps
      every minute), right ventricle function and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, double blind, placebo-controlled clinical study involving 30 patients with
      World Health Organization (WHO) Group 1 pulmonary arterial hypertension being treated with
      ambrisentan randomized to receive placebo or spironolactone (50 mg/d) for 90 days using a
      cross-over trial design.

      Eligible participants will be randomized to receive placebo or spironolactone (50 mg/d) for
      90 days (Phase I). At the completion of Phase I, participants will undergo repeat end-point
      assessment followed by a 21-day drug washout period. Then, the 90 day crossover phase of the
      trial will occur (Phase II), in which participants randomized to placebo in Phase I will be
      treated with spironolactone (50 mg/d) in Phase II and vice versa. At the conclusion of Phase
      II, end-point measures are reassessed.

      Spironolactone is a diuretic used in treatment of PAH patients. Spironolactone is usually
      added to medical treatment when doses of Lasix/Torsemide are increased and patients are at
      risk for hypokalemia.

      Study procedures being done for this research study are the standard procedures performed on
      all PAH patients when they are in clinic for follow-up except for the Cardiopulmonary
      Exercise Test (CPET) with Innocor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combination ambrisentan + spironolactone on cardiopulmonary fitness</measure>
    <time_frame>200 days</time_frame>
    <description>Study the effect of combination ambrisentan (5-10 mg/d) + spironolactone (50 mg/d) on cardiopulmonary fitness as assessed by the composite change from baseline (study drug day 1) at study drug day 90 for each of the two trial phases (See Section IV) on the following dimensions: (i) 6 minute walk distance and (ii) peak oxygen consumption (ml/kg/min)(pVO2) at the completion of exercise.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of combination ambrisentan + spironolactone on cardiac output</measure>
    <time_frame>200 days</time_frame>
    <description>Study the effect of combination ambrisentan (5-10 mg/d) + spironolactone (50 mg/d) on cardiac output assessed non-invasively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of combination ambrisentan + spironolactone on right ventricular function</measure>
    <time_frame>200 days</time_frame>
    <description>Study the effect of combination ambrisentan (5-10 mg/d) + spironolactone (50 mg/d) on right ventricular systolic function assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of combination ambrisentan + spironolactone on biochemical measures of heart failure.</measure>
    <time_frame>200 days</time_frame>
    <description>Study the effect of combination ambrisentan (5-10 mg/d) + spironolactone (50 mg/d) on biochemical measures of heart failure and collagen metabolism, including N-terminal brain natriuretic peptide, troponin, collagen III, and IL-6 levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of combination ambrisentan + spironolactone on quality of life.</measure>
    <time_frame>200 dyas</time_frame>
    <description>Study the effect of combination ambrisentan (5-10 mg/d) + spironolactone (50 mg/d) on quality of life using the SF-36 questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>AMB + Spiro, Cardiopulmonary fitness</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ambrisentan 5 or 10 mg every day (QD) Spironolactone 50 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cardiopulmonary fitness</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo mimics spironolactone 50 mg and will be taken QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambrisentan plus Spironolactone</intervention_name>
    <description>Cardiopulmonary fitness</description>
    <arm_group_label>AMB + Spiro, Cardiopulmonary fitness</arm_group_label>
    <other_name>Letairis plus Aldactone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambrisentan plus Placebo</intervention_name>
    <description>Placebo is a sugar pill manufactured to resemble spironolactone 50 mg Cardiopulmonary fitness</description>
    <arm_group_label>Placebo Cardiopulmonary fitness</arm_group_label>
    <other_name>Letairis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntarily gives informed consent to participate in the study.

          2. Right heart catheterization demonstrating conventional mean pulmonary artery pressure
             (mPAP) &gt;25, pulmonary vascular resistance (PVR) &gt;3.0 Wood Units, pulmonary capillary
             wedge pressure (PCWP) &lt;16 mmHg within two years of enrollment

          3. Subject is 18 years of age or older at Screening.

          4. Diagnosis of symptomatic idiopathic or heritable PAH, PAH associated with Connective
             Tissue Disease (CTD), PAH associated with repaired/unrepaired congenital
             systemic-to-pulmonary shunt, Portopulmonary hypertension or PAH associated with HIV
             infection.

          5. New York Heart Association Functional Class II or III

          6. Stable therapy with ambrisentan 5 or 10 mg every day for &gt; 90 days.

          7. Baseline 6-Minute Walk Distance 50-450m

        Exclusion Criteria:

          1. Substantial Primary Lung disease

               -  forced expiratory volume at one second (FEV-1)/forced vital capacity (FVC) &lt;0.6
                  and FEV-1 &lt;70% predicted

               -  diffusing capacity of lung for carbon monoxide (DLCO) &lt;30% predicted

               -  Pulmonary fibrosis

          2. Left ventricular ejection fraction &lt; 50%

          3. Pulmonary capillary wedge pressure &gt; 16 mm Hg

          4. Aortic valve disease

          5. Ischemic heart disease

          6. Systemic hypotension (SBP &lt;90 mm Hg)

          7. Co-existing treatment with other endothelin receptor antagonists or prostacyclin
             analogues

          8. New York Heart Association Functional Class IV

          9. Chronic thromboembolic pulmonary hypertension

         10. Known or suspected pulmonary veno-occlusive disease

         11. Serum creatinine &gt;2.0 mg/dL in women, Serum creatinine &gt;2.5 mg/dL in men

         12. Baseline serum potassium &gt;5.0 milliequivalent (mEq)/L

         13. Participation in ongoing drug/intervention-based clinical trial

         14. Pregnancy

         15. Unable to provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley Maron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurie Lawler, R.N.</last_name>
    <phone>617-525-9731</phone>
    <email>llawler@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bradley Maron, MD</last_name>
    <phone>617-525-9731</phone>
    <email>bmaron@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bradley Maron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2014</study_first_submitted>
  <study_first_submitted_qc>September 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Bradley Maron, MD</investigator_full_name>
    <investigator_title>Instructor in Medicine</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension (PAH)</keyword>
  <keyword>Ambrisentan</keyword>
  <keyword>Spironolactone</keyword>
  <keyword>Selective Endothelin A (ETA) inhibition</keyword>
  <keyword>Aldosterone antagonism</keyword>
  <keyword>Cardiac output (CO)</keyword>
  <keyword>Right ventricular (RV) function</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Pro-inflammatory cytokine</keyword>
  <keyword>Interleukin-6 (IL-6)</keyword>
  <keyword>Troponin-I</keyword>
  <keyword>N-terminal pro-brain natriuretic peptide (NT-BNP)</keyword>
  <keyword>Collagen metabolism</keyword>
  <keyword>N-terminal procollagen type I</keyword>
  <keyword>Collagen III</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>WHO Functional Class</keyword>
  <keyword>Cardiopulmonary Exercise Test with Innocor</keyword>
  <keyword>Peak oxygen consumption (pVO2)</keyword>
  <keyword>Liver function markers (AST/ALT)</keyword>
  <keyword>Renal function markers (creatinine and potassium)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Ambrisentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

